Syndax announces publication in the journal of clinical oncology of data from the pivotal augment-101 trial of revumenib in relapsed/refractory kmt2ar acute leukemia

– pivotal augment-101 trial met its primary endpoint at interim analysis of patients with kmt2ar aml and all (p-value = 0.0036) – – nda filing for revumenib in r/r kmt2ar acute leukemia is being reviewed under rtor; pdufa action date of december 26, 2024 – waltham, mass. , aug. 12, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal phase 2 portion of the augment-101 trial of revumenib, a first-in-class menin inhibitor, in adult and pediatric patients with relapsed/refractory (r/r) kmt2a-rearranged (kmt2ar) acute myeloid leukemia (aml) and acute lymphoid leukemia (all) have been published in the journal of clinical oncology.
KMT Ratings Summary
KMT Quant Ranking